KyungDong Pharm Co., Ltd. will launch the high-dose BPH treatment “Euronal sustained-release tablet 0.4mg” in July 2020.


“Euronal extended-release tablet 0.4mg” is a treatment for urinary disorders caused by benign prostatic hyperplasia (BPH), and is an increased version of Tamsulosin 0.2mg, which was widely used in Korea.


The advantage of “Euronal extended-release tablet 0.4mg” is that it can be prescribed for the first time without insurance reduction. The existing 0.2mg dose raised concerns about insurance cuts when administering 2T to first-time patients, but “Euronal extended-release tablet 0.4mg” can be administered as a first-line medication to first-time patients without such concerns, increasing the range of choices and convenience for prescribers.

Also, in terms of safety, “Euronal extended-release tablet 0.4mg” was not significantly different from 0.2mg.


We hope that “Euronal extended-release tablet 0.4mg” will help improve the symptoms of patients suffering from diseases related to benign prostatic hyperplasia.


♤ Product Information ♤

Product Name

Euronal extended-release tablet 0.4mg

Ingredient content

Tamsulosin hydrochloride 0.4mg

Indications

Urination disorder due to benign prostatic hyperplasia

Dosage and usage

Adults: Take 0.4 mg orally as tamsulosin hydrochloride once a day after a meal.

This medicine should be swallowed whole and should not be crushed or chewed.

Reimbursement Prices

794 won/tablet

Reimbursement Code

648104510

Packaging unit

30 tablets (10 tablets

※ Please refer to the product manual for other details such as precautions for use.